撰文丨王聪 编辑丨王多鱼 该研究发现，被趋化素激活后，GPR1 通过至少四种方式与 β-arrestin 1 结合，体现了两者从"预结合"到"稳定结合"状态的动态过程。这是首次在原子水平阐明 一种 GPCR 与 arrestin 相互作用的动态调控模式，为理解阻遏蛋白介导受体脱敏及内吞的分子机制提供了重要信息，同时也提出了靶向多种构象状态开展药物研 发的必要性，将促进开发特异性靶向阻遏蛋白信号通路的新型偏向性药物。 排版丨水成文 趋化素 （chemerin） 是一种重要的脂肪因子，参与调控脂质代谢和胰岛素敏感性，与肥胖、糖尿病等代谢性疾病的发生发展密切相关。同时，趋化素还能介导免 疫细胞定向迁移至炎症部位，参与机体抵御病原入侵、维持稳态和修复组织损伤等重要生理过程，在炎症与代谢之间发挥"桥梁"作用。 趋化素的生物学效应由其受体介导，包括 CMKLR1 和 GPR1 。其中，CMKLR1 作为一种典型的 G 蛋白偶联受体 （GPCR） ，通过 G 蛋白信号通路驱动脂质 代谢与炎症反应，而 GPR1 则是一种非典型的 GPCR，依赖于阻遏蛋白 （arrestin） 介导的信号通路和受体内吞，清除过量的趋化素。趋化 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 每经编辑｜万清澄 11月21日晚，辽宁成大股份有限公司（股票简称：辽宁成大，股票代码：600739.SH）发布公告，经董 事会审议通过，公司同意新疆宝明矿业有限公司（以下简称"新疆宝明"）长期停产。公司不再向新疆宝 明追加大额现金投入，将继续努力推动新疆宝明通过引入战略投资者的方式解决其自身的资金和发展问 题。 未来，公司将以稳健的金融资产为基础，主要聚焦生物医药等核心产业；同时，结合国家产业政策，积 极探索新质生产力相关产业投资机会，实现新的高质量发展。 2月28日，辽宁成大2025年第一次临时股东会会议审议通过董事会换届选举议案，同日，公司第十一届 董事会第一次会议选举徐飚先生为第十一届董事会董事长，聘任董事张善伟先生为公司总裁。 其中，董事长徐飚来自广东优秀民营企业设立的产业投资平台广东民营投资股份有限公司（以下简 称"粤民投"），粤民投首期创立股东包括美的集团、立白集团、海天等知名企业，平台背后具有丰富的 产业资源和资本实力。 自2020年开始，徐飚先生便担任辽宁成大第九届董事会董事，对辽宁成大的情况非常熟悉。徐飚先生现 任粤民投执行总裁，辽宁成大董事 ...

Core Viewpoint - The company, Baillie Gifford Tianheng (688506.SH), has signed a strategic cooperation agreement with the Bank of China Sichuan Branch to establish a long-term comprehensive strategic partnership, which includes a commitment to provide no less than 8 billion yuan in credit support for the company's development strategy [1] Group 1: Strategic Cooperation - The agreement involves specific business operations that will require separate contracts to be signed [1] - The Bank of China has acknowledged the funding needs faced by the company in the process of innovative drug research and industrialization [1] Group 2: Financial Support - The strategic cooperation is expected to accelerate the company's strategic layout in the global biopharmaceutical frontier, reinforcing its leading position in fields such as antibody-drug conjugates (ADC) and multi-specific antibodies [1] - This partnership aims to seize new opportunities in the global biopharmaceutical industry, promoting mutual benefits and joint development [1]

Core Insights - Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology R&D platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. focuses on circRNA technology platform development and innovative drug development, also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] Group 2: Collaboration Focus Areas - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Baijin's exosome and cell platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, cerebral infarction, Alzheimer's, and Parkinson's diseases [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

格隆汇11月19日丨佰金生命科学(01466.HK)公布，公司间接全资附属公司北京佰金生物科技有限公司 ("北京佰金")与优环(苏州)生物医药科技有限公司("优环生物")签订策略合作框架协议，据此，北京佰金 将透过认购优环生物股权的方式对优环生物进行投资，旨在打造全球领先的环状RNA(circRNA)技术研 发平台并借助此平台，深化细胞治疗领域的技术创新。订约方尚未确定相关投资的实际时间及金额。合 作框架协议将于2026年12月31日届满，协议任何一方均可提前10天通知另一方提前终止合作框架协议。 优环(苏州)生物医药科技有限公司是一家聚焦于circ RNA技术平台研发与创新药物开发并兼具CRO服务 (即医药合同研发机构服务)的双驱动生物医药企业，自主管线研发的同时，包括circ RNA设计的全流程 CRO服务。公司自主研发的「Circular RNAs and Preparation Methodsthereof(circ RNA及其制备方法)」成 功获得美国专利授权；「一种基于核酶自剪接的无残留序列环状RNA及其制备方法」成功获得中国发 明专利授权；且正与国际前沿药物研发领域大型企业开展深度合作，并在某细 ...

杭州市生物医药产业近年来实现了跨越式发展，成为全国重要的生物医药创新高地。从2000年到 2024年，总产值从40亿元增长到超1000亿元，现有规上工业企业超300家。然而，随着产业的枝繁叶 茂，推动协同创新，正成为大家共同的期盼。 日前，全市生物医药产业科技创新和产业创新融合对接座谈会举行。记者冒着淅淅沥沥的秋雨赶到 会场，推开门，暖意扑面而来——回字形摆放的会议桌前坐得满满当当，大家翻阅着面前的会议资料， 了解高校、科研院所、医疗机构和企业的情况。 "组织这场活动，就是希望搭建一个平台，让'科研端'的智慧与'产业端'的需求能够直接对话。"主 持人开门见山。 听到高等院校、科研院所代表提到的先进技术，贝达药业股份有限公司副总裁兰宏尤其兴奋。"我 们非常感兴趣！"他说，"作为企业研发人员，我认为企业更擅长临床阶段，比如把有苗头的分子进一步 优化，推进临床开发，而这个苗头分子的出现是我们需要寻找的，非常希望与科技创新界建立合作。" 雨声渐密，市经信局工作人员的笔记本记了满满两页纸，"我们会尽快梳理交流成果，推动各方需 求与资源的精准匹配，让今天的'好想法'变成未来的'好项目'。" 散会时已是黄昏，但参会代表们都 ...

Core Viewpoint - The company emphasizes the importance of innovation in drug development for oncology, autoimmune diseases, and neurobiology, highlighting unmet clinical needs and significant market demand in these areas [1] Group 1: Oncology - Oncology remains a key focus for innovative drug development, with ongoing clinical demand for breakthroughs in immunotherapy, targeted therapy, and personalized medicine due to increasing drug resistance [1] Group 2: Autoimmune Diseases - Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are critical areas of interest for biopharmaceutical companies, particularly as they affect the younger workforce and have lower treatment efficacy and adherence [1] Group 3: Neurobiology - Neurodegenerative diseases like Alzheimer's, Parkinson's, and diabetic neuropathy are gaining significant attention from global pharmaceutical companies and research institutions, driven by the rapid increase in patient numbers due to global aging [1] Group 4: Company Pipeline - The company has established multiple self-developed drug pipelines in neurobiology, autoimmune diseases, and oncology, having obtained three IND approvals for Class I new drugs and ten IND approvals for Class II new drugs [1]

Market Overview - The Hong Kong stock market opened lower today, with the Hang Seng Index at 26,172.27 points, down 212.01 points, a decline of 0.80% [1] - The Hang Seng Tech Index reported at 5,684.81 points, down 72.07 points, a decrease of 1.25% [2] Company Performance - XPeng Motors (09868.HK) saw a drop of over 7% in early trading. The company reported total revenue of RMB 20.38 billion for Q3, a year-on-year increase of 101.8%. The net loss attributable to ordinary shareholders was RMB 380 million (USD 50 million), compared to RMB 1.81 billion in the same period last year [4] - Leap Motor (09863.HK) experienced a decline of over 2%. The company announced a net profit of RMB 150 million for Q3 2025, with a total net profit of RMB 180 million for the first three quarters. The gross margin for Q3 was 14.5%, up 0.9 percentage points from Q2 2025, with total vehicle deliveries of 173,852 units and revenue of RMB 19.45 billion, a year-on-year growth of 97.3% [6] - Geely Automobile (00175.HK) reported Q3 2025 revenue of RMB 89.192 billion, a year-on-year increase of 27%. The net profit attributable to shareholders surged by 59% to RMB 3.82 billion [6] Sector Performance - The technology sector saw widespread declines, with Kuaishou, Tencent, NetEase, and Baidu all dropping over 1%. Alibaba opened down over 1% but quickly rebounded [7] - Insurance stocks opened lower, with AIA Group falling over 1%. Gold stocks also retreated, with Chifeng Jilong Gold Mining and Zijin Mining down over 2% [7] - The biopharmaceutical sector showed signs of recovery, with BeiGene and Zai Lab rising over 4%. The semiconductor sector strengthened, with Hua Hong Semiconductor and SMIC both up over 1% [7] Market Outlook - Morgan Stanley has set a mid-to-long-term target for the Hang Seng Index at 27,500 points, with a bullish scenario reaching 34,700 points and a bearish scenario potentially dropping to 18,700 points. This outlook considers potential liquidity improvements, such as the Federal Reserve possibly halting balance sheet reduction in December, along with the anticipated "spring rally" early next year. However, external factors like Federal Reserve policies and U.S. stock market volatility remain significant variables [8]

和铂医药 20251117 摘要 诺纳生物定位为提供一站式或整合式交付的创新 CRO，区别于传统 CRO 的碎片化服务，通过科学家自主想法和全球竞争力平台，为客户创 造价值，交付 License out 产品，如 binder、PCC 或 IND。 诺纳生物拥有四大关键技术平台，包括 HMI 人源化转基因小鼠平台、 ADC/RDC/AOC 递送系统、新型体内 CAR 体系和 AI 研发平台，这些平 台不仅支持内部管线，也为全球企业提供服务。 诺纳生物计划未来三年从 Discovery 阶段扩展到 CMC 和临床概念验证 阶段，通过与 GLP 和 CDMO 公司合作，提升 GLP 延展能力和高端制剂 研发能力，并在上海建立 AI 创新中心。 诺纳生物通过 Humanetics 平台形成数字化合作小组，结合干湿实验提 升药物研发成功率，并在临床后端与顶级医院合作，构建"数字人"以 提高数字化临床试验效率。 和铂医药的 4,003 项目是一种 Treg 细胞清除疗法，在临床前研究中显 示出显著效果，清除肿瘤微环境中的 Treg 细胞的效力是对照组的 100 倍，并在多个适应症中展现出潜力。 Q&A 诺纳生物的创新战 ...

近日，百利天恒（688506.SH）宣布，其自主研发的全球首创（First-in-class）、新概念（New concept） 且唯一进入III期临床阶段的EGFR×HER3双抗ADC（iza-bren）在食管鳞癌的III期临床试验（研究方案 编号：BL-B01D1-305）中，经独立数据监查委员会（iDMC）判断，在预设的期中分析中达到无进展生 存期（PFS）和总生存期（OS）双主要终点，适应症为：既往经PD-1/PD-L1单抗联合含铂化疗治疗失 败的复发性或转移性食管鳞癌。这是全球首个ADC药物在食管癌治疗中取得PFS/OS双阳性结果的III期 临床研究。 BL-B01D1-305研究的期中分析结果表明，iza-bren相比化疗，期中分析达到研究的无进展生存期 （PFS）和总生存期（OS）双主要终点，研究结果具有统计学显著获益和重大临床获益。值得一提的 是，该适应症已被国家药品监督管理局药品审评中心（CDE）纳入突破性治疗品种名单，百利天恒将于 近期向CDE递交上市前沟通交流申请，预计明年国内商业化落地。食管鳞癌市场潜力巨大，中国食管癌 患者占全球53.7%，且晚期食管鳞癌(ESCC)患者5年生存率不足 ...